Effect of Quetiapine, from Low to High Dose, on Weight and Metabolic Traits: Results from a Prospective Cohort Study

Abstract Introduction The atypical antipsychotic quetiapine is known to induce weight gain and other metabolic complications. underlying mechanisms are multifactorial poorly understood with almost no information on the effect of dosage. Concerns were thus raised rise in low-dose off-label prescription (i. e.,<150 mg/day). Methods In this study, we evaluated influence dose for 474 patients included PsyMetab PsyClin studies parameter evolution. Weight, blood pressure, lipid, glucose profiles during a follow-up period 3 months after treatment initiation. Results Significant dose-dependent alterations observed. daily was found increase risk undergoing clinically relevant (?7% from baseline). It also associated change plasma levels cholesterol (total cholesterol, LDL HDL cholesterol) as well increased odds developing hypertriglyceridemia, total hypercholesterolemia. No impact pressure level Discussion highlighted lipid emphasizes importance prescribing minimal effective dose. However, size worsening low, potential harm should not be dismissed. Prescriptions must carefully regularly questioned light side onset.